Hydrochlorothiazide / propranolol Side Effects
Not all side effects for hydrochlorothiazide / propranolol may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to hydrochlorothiazide / propranolol: oral capsule extended release, oral tablet
Along with its needed effects, hydrochlorothiazide / propranolol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking hydrochlorothiazide / propranolol:Incidence not known
- Abdominal or stomach pain, usually after eating a meal
- abdominal or stomach tenderness
- black, tarry stools
- bleeding gums
- blistering, peeling, or loosening of the skin
- blood in the urine
- bloody nose
- bloody stools
- blurred or loss of vision
- body aches or pain
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- chest pain or discomfort
- clay-colored stools
- cold sweats
- confusion about identity, place, and time
- coughing up blood
- cracks in the skin
- darkened urine
- decreased awareness or responsiveness
- decreased urine output
- difficulty with breathing or swallowing
- dilated neck veins
- disturbed color perception
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- double vision
- dry mouth
- dryness or soreness of the throat
- extreme fatigue
- fast, pounding, slow, or irregular heartbeat
- fever or chills
- flushing or redness of the skin
- fruit-like breath odor
- general feeling of discomfort or illness
- general feeling of tiredness or weakness
- hair loss
- halos around lights
- heavier menstrual periods
- hives or welts
- increased hunger
- increased sensitivity of the skin to sunlight
- increased thirst
- increased urination
- irregular breathing
- irregular heartbeat
- joint pain, stiffness, or swelling
- lightheadedness, dizziness, or fainting
- loss of appetite
- loss of heat from the body
- loss of strength or energy
- lower back or side pain
- mental depression
- mimicry of speech or movements
- muscle pain or weakness
- nausea or vomiting
- night blindness
- noisy breathing
- overbright appearance of lights
- painful or difficult urination
- pains in the stomach, side, or abdomen, possibly radiating to the back
- paleness or cold feeling in the fingertips and toes
- peculiar postures or movements, mannerisms or grimacing
- pinpoint red or purple spots on the skin
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- quick to react or overreact emotionally
- rapidly changing moods
- rectal bleeding
- red skin lesions, often with a purple center
- red, irritated eyes
- red, swollen skin
- reddening of the skin, especially around the ears
- runny nose
- scaly skin
- seeing, hearing, or feeling things that are not there
- severe sleepiness
- severe sunburn
- short-term memory loss
- shortness of breath
- skin irritation or rash, including rash that looks like psoriasis
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- sugar in the urine
- swelling of the eyes, face, or inside of the nose
- swelling of the fingers, feet, or lower legs
- tender, swollen, or painful glands in the neck
- tenderness of salivary glands
- tenderness, burning, or peeling of the skin
- thickening of bronchial secretions
- tightness in the chest
- tingling or pain in the fingers or toes when exposed to cold
- trouble with sleeping
- trouble with swallowing
- troubled breathing
- tunnel vision
- unable to sleep
- unpleasant breath odor
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight loss
- unusually warm skin
- voice changes
- vomiting of blood
- weight gain
- yellow eyes or skin
Get emergency help immediately if any of the following symptoms of overdose occur while taking hydrochlorothiazide / propranolol:Symptoms of overdose
- Change in consciousness
- decreased urination
- fast, slow, or shallow breathing
- increase in heart rate
- increased sweating
- loss of consciousness
- low blood pressure
- muscle cramps
- pale or blue lips, fingernails, or skin
- rapid breathing
- sunken eyes
- unusual drowsiness, dullness, or feeling of sluggishness
- unusual paleness
- weakness and heaviness of the legs
- wrinkled skin
Some side effects of hydrochlorothiazide / propranolol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Incidence not known
- Decreased interest in sexual intercourse
- dry eyes
- feeling of constant movement of self or surroundings
- inability to have or keep an erection
- loss in sexual ability, desire, drive, or performance
- muscle spasm
- pain of the penis on erection
- pain or discomfort in the chest, upper stomach, or throat
- sensation of spinning
- stomach cramps
- thinning of the hair
- vivid dreams
For Healthcare Professionals
Applies to hydrochlorothiazide / propranolol: oral capsule extended release, oral tablet
Use of a nonselective beta-blocker like propranolol may at least blunt cardiac output in some patients, especially those with preexisting left ventricular systolic dysfunction and during exertion. Data have shown that cardiac conditioning can delay or attenuate this side effect of propranolol.
Abrupt cessation of propranolol therapy may result in hypertension, myocardial infarction, and angina pectoris in some patients.
Paradoxical hypertension may occur in patients with pheochromocytoma unless alpha-adrenergic blockade is already instituted.
At least two cases of electrical alternans associated with propranolol have been reported from pediatric cases. In one case, electrical alternans was clearly not rate-related (since it occurred during propranolol therapy at a slower rate than the patient's "native" ventricular tachycardia) and was associated with echocardiographically-demonstrated mechanical alternans.
Cardiovascular side effects are the most common, and include hypotension, bradycardia, syncope, and exacerbation of Raynaud's phenomenon, atrioventricular block, and/or congestive heart failure (CHF). Hydrochlorothiazide (HCTZ)-induced hypokalemia or hyponatremia may predispose some patients to cardiac arrhythmias including ventricular ectopy and complete AV heart block. Rare cases of hypotension have been associated with HCTZ-induced acute pulmonary edema (probably due to hypersensitivity).
Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and may reduce insulin secretion, it should be used with caution in diabetic patients and in those with hypercholesterolemia. Propranolol may also adversely affect the lipid profile.
Hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.
Metabolic side effects associated with HCTZ are more likely with daily doses of 50 mg or more. Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50%, and may predispose patients to cardiac arrhythmias. Metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, and elevated serum uric acid levels are also relatively common. Use of HCTZ may increase serum cholesterol levels.
A 68-year-old man with a history of myocardial infarction (MI) developed dyspnea, chest tightness, a low grade fever, dizziness, sweating, and vomiting associated with cyanosis, a mild leukocytosis, radiographic evidence of pulmonary edema, clinical evidence of hypovolemia, and respiratory acidosis. MI and infection were ruled out; the patient recovered after restoration of his intravascular volume with saline and albumin. The only precipitating factor per history was the ingestion of HCTZ, which the patient had taken without incident for two years. Rechallenge resulted in recurrent acute pulmonary edema. Other signs of hypersensitivity, such as rash and eosinophilia, were absent.
Hypersensitivity reactions are rare. They often present as nausea, vomiting, diarrhea, or rash and occur in less than 1% of patients. Cases of acute pulmonary edema, interstitial cystitis, interstitial nephritis, and anaphylaxis have been associated with the use of this combination drug.
Nervous system side effects may be related to the dose of propranolol. Fatigue, dizziness, impaired sleep, and dreams occur in approximately 2% to 5% of patients. Rare cases of cerebrovascular insufficiency have been associated with HCTZ-induced plasma volume contraction.
Rare cases of paresthesias associated with propranolol have been reported.
There are reports of patients with renal insufficiency who experienced a reversible decline in renal function without a decline in systemic blood pressure during propranolol therapy. Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition has been reported.
Renal side effects including new or worsened renal insufficiency, related to lowering of systemic blood pressure and intravascular volume depletion, has occurred in less than 1% of patients. Rare cases of interstitial nephritis have been reported.
Limited data have shown a mean fall in maximal midexpiratory flow rate (MMFR) during propranolol therapy relative to placebo in nine of ten patients. Interestingly, the fall was not related to smoking or to atopic status, suggestive of resting beta-adrenergic bronchodilator activity in nonasthmatic subjects.
Nonselective beta-blockers, such as propranolol, are used with caution in patients with asthma and chronic obstructive pulmonary disease due to inhibition of bronchodilation.
Respiratory side effects include potential worsening of reactive airways diseases. Some large studies have shown that many patients, regardless of a history of lung disease, complain of dyspnea during propranolol monotherapy. Approximately 30 case reports of acute noncardiogenic pulmonary edema have been associated with HCTZ. The mechanism is unknown, but some evidence points towards hypersensitivity.
Endocrine side effects have been reported. Both drugs are associated with endocrinologic problems that may be important in some patients with or who are at risk for diabetes or coronary artery disease. Each may cause hyperglycemia (glucose intolerance) and have a potentially deleterious effect on the serum lipid profile. Propranolol, like other nonselective beta-blockers, can mask some signs of hypoglycemia, such as sweating and tachycardia.
A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed an increased mean fasting blood glucose level after treatment. Withdrawal of thiazide therapy for 7 months in 10 of the patients resulted in mean reductions of 10% in fasting blood glucose and 25% in the 2-hour glucose tolerance test value. A control group was not reported.
Gastrointestinal side effects, such as diarrhea, nausea, constipation, and vomiting, are usually transient. Rare cases of elevated liver function tests have been associated with propranolol and rare cases of pancreatitis and acute cholecystitis have been associated with HCTZ.
Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion were reported in the 1960's, although these patients were on a combination HCTZ-potassium product.
Dermatologic reactions associated with the use of HCTZ include erythema annular centrifugum, acute eczematous dermatitis, and morbilliform or leukocytoclastic vasculitis. Thiazides may induce phototoxic dermatitis. In addition, a rare, distinct entity with clinical and laboratory features indistinguishable from those of subacute cutaneous lupus erythematosus has been associated with HCTZ. Rare cases of psoriatic flares have been associated with propranolol. Other cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria, have been associated with use of propranolol.
A 67-year-old white woman with hypothyroidism, hypercalcemia, depression, and hypertension developed facial erythema, headaches, tremors, confusion, and personality changes associated with a new positive ANA and anti-nRNP and a skin biopsy consistent with lupus erythematosus while taking HCTZ, levothyroxine, and amitriptyline. The eruption resolved upon discontinuation of HCTZ, but she later developed a higher ANA titer associated with symptomatic diffuse interstitial pulmonary infiltrates. She was successfully treated with corticosteroids.
One study of 34 hypertensive patients who were taking propranolol found an incidence of depressive symptoms ranging from 50% to 74% (depending on the criteria used). Propranolol-induced depression may be more likely in patients with a personal or family history of depression. Of the 34 patients, 12 had a history of depression and 8 had a history of substance abuse, alcoholism, or a family history of psychiatric disorders. Since none of the 12 patients with a history of depression were clinically depressed at the start of propranolol therapy and were similar in age, diagnosis, and propranolol dosage to the other 22 patients, a comparison was made. Patients with a personal or family history of depression had significantly higher scores on depression scales than those without such histories.
Rare cases of psychoses associated with propranolol have been reported.
Psychiatric depression has been associated with the use of beta-blockers, particularly the more lipophilic, nonselective beta-blockers like propranolol. Well-described cases of major depressive episodes after initiation of propranolol therapy, which were dose-dependent and remittent upon drug discontinuation, have been reported.
Musculoskeletal pains, sometimes associated with chills, have been associated with HCTZ-induced diuresis.
Hematologic side effects associated with either drug are rare. Rare cases of purpura with and without normal platelet counts and cases of agranulocytosis have been associated with the use of propranolol, and rare cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia have been associated with the use of HCTZ.
There are rare case reports of HCTZ-induced immune hemolytic anemia. The following illustrates a fatal case:
A 53-year-old man with hypertension developed nausea, vomiting, diarrhea, and progressive anorexia and weakness associated with scleral icterus, anemia with spherocytosis, dark red urine with proteinuria, bilirubinuria, hemoglobinuria, and elevated serum lactate dehydrogenase levels 18 months after beginning HCTZ and methyldopa. Haptoglobin was less than 50 mg/dL. Direct and indirect Coombs tests were positive. The patient died suddenly; autopsy revealed no obvious cause of death, left ventricular hypertrophy, and mild coronary atherosclerosis.
Immunologic side effects have not been reported. Limited data have shown that propranolol can enhance the immune system. The clinical significance of this is unknown.
Propranolol can enhance the immune system by causing an increase in the number of circulating T cells, increased interleukin-2 (IL-2) secretion, increased expression of IL-2 receptors, and increased lymphocyte production in response to the T cell mitogen Con A. Interestingly, NK cell activity may be decreased during propranolol therapy, although the number of circulating NK cells may remain unchanged. These results are consistent with previous data showing decreased immunologic function during periods of elevated sympathetic activity, such as congestive heart failure, uremia, or life-threatening events.
Ocular side effects have included idiosyncratic reactions to the hydrochlorothiazide component resulting in acute transient myopia and acute angle-closure glaucoma.
More about hydrochlorothiazide/propranolol
- Hydrochlorothiazide and propranolol
- Propranolol and hydrochlorothiazide (Advanced Reading)
- Other brands: Inderide
- Propranolol and Hydrochlorothiazide (FDA)
- Propranolol Hydrochloride/Hydrochlorothiazide (HCTZ) (Wolters Kluwer)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.